TIDMFDBK
RNS Number : 8842M
Feedback PLC
19 October 2016
This announcement contains inside information as stipulated
under the Market Abuse Regulation (EU) No 596/2014 (MAR).
19 October 2016
Feedback plc
('Feedback' or "the Company')
Final results for the year ended 31 May 2016
Notice of Annual General Meeting
Feedback plc is pleased to announce its final results for the
year ended 31 May 2016.
CHAIRMAN'S STATEMENT FOR THE YEARED 31 MAY 2016
We are pleased to present the results for the year ended 31 May
2016. Revenue for the year was GBP431,454 (2015: GBP381,970) and
the loss after tax was GBP183,156 (2015: Loss GBP1,111,433). Cash
as at 31 May 2016 was GBP105,673 (31 May 2015: GBP63,261). Cash as
at 13 October 2016 was GBP94,629.
The results show growth in revenue and a substantial reduction
in the loss after tax. Cash generation has been better than
anticipated and reflects payments received from customers in
respect of purchase orders before revenue is recognised. Cambridge
Computed Imaging Limited ("CCI") performed steadily during the year
as it continued to serve its established customer base. Revenue
recognised from TexRAD research version sales was higher than in
the previous year. In line with management's expectations, there
was a reduction in new purchase orders for TexRAD research versions
during the year although there remained a good deal of customer
interest from research institutions which were looking to obtain
grant funding. Dr Balaji Ganeshan continued to lead the sales
effort and his hard work has led to a high level of orders received
after the year end from world-renowned institutions carrying out
oncology research. The Company has also signed collaborative
agreements with companies in Japan and South Korea to explore
further selling opportunities in these markets for TexRAD research
versions which has had some success. In order to support our
research customers we have been looking at ways to assist them in
analysing and interpreting the results of their studies. We are
working on one such project and this could prove to be a useful
additional source of revenue in the future. Dr Ganeshan has been
continuing his work supporting research into new potential
applications of TexRAD. This has led to the publication of
scientific papers on TexRAD's use in assessing different types of
carcinomas as well as a number of presentations at scientific
conferences including the Beijing Society of Radiology in China and
participation in Healthtech Week in Auckland, New Zealand.
In November 2015 the Company announced that it had signed a
Memorandum of Understanding with Alliance Medical Group
("Alliance") with the intention of integrating Feedback's TexRAD
texture analysis software into Alliance's PET-CT lung cancer
imaging service. The Company has made good progress on a technical
solution that would allow the integration of TexRAD into Alliance's
network of PET/CT scanners in UK hospitals and a prototype version
has been demonstrated to potential users. The next steps will
include applying for a CE mark for a medical device which provides
analysis of lung PET/CT images with added prognostication through
TexRAD. An abstract has been accepted by the Radiological Society
of North America (RSNA) for presentation at its annual conference
in November 2016 which will highlight the results from the
technical and clinical evaluation. Further abstracts publishing the
research findings of our customers using TexRAD have also been
accepted for presentation at RSNA.
During the financial year the Company formed two joint venture
companies, Stone Checker Software Ltd and Prostate Checker Ltd.
Both companies offer the prospect of developing innovative
solutions where routine medical images can provide useful
additional information for clinicians. The Company sold its 50%
equity interest in Stone Checker Software Ltd to Free Association
Books Ltd in May 2016 resulting in a gain of GBP45,000.
After the year end Feedback announced a large-scale
collaboration with Future Processing Sp. z o.o. ("Future
Processing"), a software development service provider based in
Gliwice, Poland to develop medical imaging software. The
collaboration will entail a substantially increased development
team working on new products and the sharing of intellectual
property and future revenues. This collaboration has resulted from
Feedback's assistance with a successful EU grant application made
by Future Processing. The directors of Feedback believe that by CCI
working jointly with the Future Processing healthcare team, CCI's
existing product portfolio can be improved and new products
developed more rapidly including further applications for TexRAD.
Although at this stage only a non-binding letter of intent has been
agreed, the intention is for the Company to agree formal licences
for new software products to be brought to market in 2017/18 under
a shared revenue arrangement. In the current financial year, the
Company expects to make substantial savings in software development
costs and thereafter expects to benefit from its share of the
revenue from sales of new products.
On 1 June 2016, after the year end, the Company announced my
appointment as its new chairman with Tom Charlton moving to
non-executive deputy chairman. I have extensive experience of
managing companies in the healthcare sector and I look forward to
assisting the Company to the next stage of its development.
We remain encouraged by the continued interest shown in TexRAD
and the number of research papers being published which highlight
its numerous potential applications. The high level of purchase
orders for TexRAD research versions which have been received after
the year end should lead to a substantial increase in revenue in
the second half of the 2016/17 year and growth in revenue for the
year as a whole. We believe there will be opportunities to make
further sales of TexRAD research versions in China by partnering
with a company with a strong local presence. We are also
considering other business relationships which could increase sales
of TexRAD research versions in other territories. In addition to
the TexRAD sales, Feedback now has the opportunity to grow its
revenues through the collaboration with Future Processing and the
development of a CE marked product for analysis of lung PET/CT
images. We will look at investing in product development,
regulatory and marketing resource to support our very positive
growth prospects.
Dr A J Riddell
Chairman
18 October 2016
For further information, contact:
Feedback plc Tel: 01954 718072
Alastair Riddell
Allenby Capital Limited (Nominated Adviser and Joint Broker) Tel: 020 3328 5656
David Worlidge / James Thomas
Peterhouse Corporate Finance Ltd (Joint Broker) Tel: 020 7469 0936
Lucy Williams / Duncan Vasey
STATEMENT OF COMPREHENSIVE INCOME FOR THE YEARED 31 MAY 2016
Note 2016 2015
GBP GBP
REVENUE 431,454 381,970
Cost of sales (7,438) (1,434)
------------ --------------
GROSS PROFIT 424,016 380,536
Other operating expenses (676,596) (888,600)
Impairment of intangible assets 7 - (689,142)
------------ --------------
Total operating expenses (676,596) (1,577,742)
------------ --------------
OPERATING LOSS (252,580) (1,197,206)
Net finance income 1,361 908
------------ --------------
Loss on ordinary activities before
taxation (251,219) (1,196,298)
Tax credit 23,063 84,865
------------ --------------
LOSS ON ORDINARY ACTIVITIES AFTER
TAX (228,156) (1,111,433)
------------ --------------
Profit on disposal of investment 5 45,000
------------ --------------
Loss for the year attributable
to the equity shareholders of
the Company (183,156) (1,111,433)
Other comprehensive income/(expense)
Translation differences on overseas
operations - 108
------------ --------------
Total comprehensive expense for
the year (183,156) (1,111,325)
============ ==============
LOSS PER SHARE (pence)
Basic and diluted 4 (0.09) (0.58)
============ ==============
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEARED 31
MAY 2016
GROUP Share Share Capital Retained Translation Convertible Total
Capital Premium Reserve Earnings Reserve Debt
Option
Reserve
GBP GBP GBP GBP GBP GBP GBP
At 1 June 2014 476,867 1,409,334 299,900 (966,339) (210,104) 189,000 1,198,658
Share option
and warrant
costs - - - 1,289 - - 1,289
Total comprehensive
expense for
the year - - - (1,111,433) 108 - (1,111,325)
--------- ---------- --------- ------------- ------------- ------------ -------------
At 31 May 2015 476,867 1,409,334 299,900 (2,076,483) (209,996) 189,000 88,622
--------- ---------- --------- ------------- ------------- ------------ -------------
New Shares issued 32,318 190,382 - - - - 222,700
Costs associated
with the
raising of funds - (6,580) - - - - (6,580)
Share option
and warrant
costs - - - 8,163 - - 8,163
Total comprehensive
expense for
the year - - - (183,156) - - (183,156)
--------- ---------- --------- ------------- ------------- ------------ -------------
At 31 May 2016 509,185 1,593,136 299,900 (2,251,476) (209,996) 189,000 129,749
========= ========== ========= ============= ============= ============ =============
COMPANY Share Share Retained Convertible Total
Capital Premium Earnings Debt
Option
Reserve
GBP GBP GBP GBP GBP
At 1 June 2014 476,867 1,409,334 (875,918) 189,000 1,199,283
Share option
and warrant
costs - - 1,289 - 1,289
Total comprehensive
expense for
the year - - (1,172,124) - (1,172,124)
At 31 May 2015 476,867 1,409,334 (2,046,753) 189,000 28,448
--------- ------------- ------------- ------------ -------------
New shares issued 32,318 190,382 - - 222,700
Costs associated
with the
raising of funds - (6,580) - - (6,580)
Share option
and warrant
costs - - 8,163 - 8,163
Total comprehensive
expense for
the year - - (224,563) - (224,563)
At 31 May 2016 509,185 1,593,136 (2,263,153) 189,000 28,168
========= ============= ============= ============ =============
CONSOLIDATED BALANCE SHEET AT 31 MAY 2016
2016 2015
Notes GBP GBP
ASSETS
Non-current assets
Property, plant and equipment 6 3,639 6,915
Intangible assets 7 110,747 139,558
Investments 5 1,000 -
------------ ------------
115,386 146,473
Current assets
Trade receivables 40,894 110,870
Other receivables 8 63,910 101,259
Cash and cash equivalents 105,673 63,261
------------ ------------
210,477 275,390
Total assets 325,863 421,863
============ ============
EQUITY
Capital and reserves attributable
to the Company's equity shareholders
Called up share capital 10 509,185 476,867
Share premium account 1,593,136 1,409,334
Capital reserve 299,900 299,900
Translation reserve (209,996) (209,996)
Retained earnings (2,251,476) (2,076,483)
------------ ------------
(59,251) (100,378)
Convertible debt option reserve 189,000 189,000
TOTAL EQUITY 129,749 88,622
LIABILITIES
Deferred tax liabilities 19,378 27,911
------------ ------------
19,378 27,911
Current liabilities
Trade payables 21,546 40,368
Other payables 9 155,190 264,962
176,736 305,330
------------ ------------
Total liabilities 196,114 333,241
------------ ------------
TOTAL EQUITY AND LIABILITIES 325,863 421,863
============ ============
COMPANY BALANCE SHEET AT 31 MAY 2016
2016 2015
Notes GBP GBP
ASSETS
Non-current assets
Investments 5 1,000 -
1,000 -
Current assets
Other receivables 8 16,661 52,993
Cash and cash equivalents 60,492 43,636
------------ ------------
77,153 96,629
------------ ------------
Total assets 78,153 96,629
============ ============
EQUITY
Capital and reserves
attributable to the
Company's equity shareholders
Called up share capital 10 509,185 476,867
Share premium account 1,593,136 1,409,334
Retained earnings (2,263,153) (2,046,753)
------------ ------------
(160,832) (160,552)
Convertible debt option
reserve 189,000 189,000
------------ ------------
TOTAL EQUITY 28,168 28,448
Current liabilities
Trade payables 16,901 33,723
Other payables 9 33,084 34,458
Total current liabilities 49,985 68,181
------------ ------------
Total Equity and Liabilities 78,153 96,629
============ ============
CONSOLIDATED CASH FLOW STATEMENT FOR THE YEARED 31 MAY 2016
2016 2015
GBP GBP
Cash flows from operating
activities
Loss before tax (251,229) (1,196,298)
---------- ------------
Adjustments for:
Share option costs 8,163 1,289
Net finance income (1,361) (908)
Depreciation and amortisation 46,052 184,170
Impairment of intangible
assets - 689,142
Decrease/(Increase)in
trade receivables 69,976 (23,260)
Decrease in other receivables 42,402 52,396
Decrease in trade payables (18,852) (184,789)
Decrease in other payables (109,772) (163,588)
Corporation tax received 9,506
---------- ------------
46,114 554,560
---------- ------------
Net cash used in operating
activities (205,105) (641,738)
Cash flows from investing
activities
Purchase of tangible fixed
assets (104) (9,329)
Purchase of intangible
assets (13,860) (161,012)
Net finance income received 1,361 908
Proceeds from sale of 46,000 -
joint venture
Purchase of shares in
joint ventures (2,000)
Net cash generated/(used
by) from investing activities 31,397 (169,433)
Cash flows from financing
activities
Net proceeds of share 216,120 -
issue
---------- ------------
Net cash generated from 216,120 -
financing activities
---------- ------------
Net increase/(decrease)
in cash and cash equivalents 42,412 (811,171)
Cash and cash equivalents
at beginning of year 63,261 874,432
Cash and cash equivalents
at end of year 105,673 63,261
========== ============
COMPANY CASH FLOW STATEMENT FOR THE YEARED 31 MAY 2016
2016 2015
GBP GBP
Cash flows from operating
activities
Loss before tax (224,563) (1,172,124)
Adjustments for:
Share options costs 8,163 1,289
Profit on sale of investments (45,000) -
Net finance income (1,356) -
Provision against intercompany
receivable 49,880 356,693
Provision against investment
in subsidiaries - 467,455
(Increase)/decrease in other
receivables (13,548) 49,221
Decrease in trade payables (16,822) (125,014)
(Decrease)/increase in other
payables (1,374) 2,670
---------- ------------
(20,057) 752,314
---------- ------------
Net cash used in operating
activities (244,620) (419,810)
Cash flows from investing
activities
Loans to subsidiary undertakings - (155,000)
Net finance income 1,356 -
Purchase of joint ventures (2,000) -
Proceeds on sale of joint
venture 46,000 -
---------- ------------
Net cash generated from/(used
in) investing activities 45,356 (155,000)
Cash flows from financing
activities
Net proceeds of share issue 216,120 -
---------- ------------
Net cash generated from 216,120 -
financing activities
Net increase/(decrease)
in cash and cash equivalents 16,856 (574,810)
Cash and cash equivalents
at beginning of year 43,636 618,446
---------- ------------
Cash and cash equivalents
at end of year 60,492 43,636
========== ============
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEARED 31 MAY 2016
1. General information
The Company is a public limited company domiciled in the United
Kingdom and incorporated under registered number 00598696 in
England and Wales. The Company's registered office is Unit 5,
Grange Park, Broadway, Bourn, Cambridgeshire, CB23 2TA.
The Company is admitted to trading on the AIM market of the
London Stock Exchange. These Financial Statements were authorised
for issue by the Board of Directors on the 18 October 2016.
2. Adoption of new and revised International Financial Reporting Standards
No new International Financial Reporting Standards ("IFRS"),
amendments or interpretations became effective in the year ended 31
May 2016 which had a material effect on this financial
information.
At the date of approval of this financial information, the
following IFRS Standards and Interpretations, which have not been
applied in these Financial Statements, were in issue but not yet
effective. These new Standards, Amendments and Interpretations are
those in issue but not yet effective which are expected to apply to
the Group and are effective for accounting periods beginning on or
after the dates shown below:
IFRS Standards and Interpretations issued (and EU adopted) but
not yet effective:
o IFRS 9 Financial Instruments (effective periods beginning 1
January 2018)
o IFRS 15 Revenue from Contracts with Customers (effective
periods beginning 1 January 2018)
o IFRS 16 Leases (effective periods beginning 1 January
2019)
The Group has not early adopted these amended standards and
interpretations. The Directors do not anticipate that the adoption
of these standards and interpretations will have a material impact
on the reported results.
3. SIGNIFICANT ACCOUNTING POLICIES
(a) Basis of preparation
These financial statements have been prepared in accordance with
those IFRS standards and IFRIC interpretations issued and effective
or issued and early adopted as at the time of preparing these
statements. The policies set out below have been consistently
applied to all the years presented.
No separate income statement is presented for the parent Company
as provided by Section 408, Companies Act 2006.
(b) Basis of consolidation
The Group financial statements consolidate the financial
statements of Feedback plc and its subsidiaries (the "Group") for
the years ended 31 May 2015 and 2016 using the acquisition
method.
The financial statements of subsidiaries are prepared for the
same reporting year as the parent company, using consistent
accounting policies. All inter-company balances and transactions,
including unrealised profits arising from them, are eliminated.
Subsidiaries are fully consolidated from the date on which control
is transferred to the Group and cease to be consolidated from the
date on which control is transferred out of the Group. Interests in
joint ventures are accounted for using the equity method, after
initially being recognised at cost within the consolidated balance
sheet. The Group's joint ventures did not trade in the year.
(c) Going Concern
The Directors consider that the Group and the Company are likely
to have access to adequate cash resources for at least the next
twelve months from the date of this report from a combination of
operational cash generation and by obtaining equity finance from
the financial markets or by way of loans from the major
shareholders. The Directors believe that the company is a going
concern and have therefore prepared the financial statements on a
going concern basis.
4. LOSS PER SHARE
. Basic earnings per share is calculated by reference to the
loss on ordinary activities after taxation of GBP195,631 (2015:
GBP1,111,433) and on the weighted average of 203,514,709 (2015:
190,746,746) shares in issue.
.
As at 31 As at
May 2016 31 May
2015
GBP GBP
Net loss attributable
to ordinary equity
holders (189,156) (1,111,433)
============ ============
As at 31 As at
May 2016 31 May
2015
Weighted average
number of ordinary
shares for basic
earnings per share 203,514,709 190,746,746
Effect of dilution:
Share Options - -
Warrants - -
------------ ------------
Weighted average
number of ordinary
shares adjusted
for the effect
of dilution 203,514,709 190,746,746
============ ============
Loss per share
(pence)
Basic (0.09) (0.58)
Diluted (0.09) (0.58)
There is no dilutive effect of the share options and warrants as
the dilution would be negative.
5. INVESTMENTS
Share Shares Total
in group in joint
undertakings venture
GBP
COMPANY
Cost
At 1 June 2014 2,334,455 - 2,334,455
-------------- ------------ -----------
At 31 May 2015 2,334,455 - 2,334,455
-------------- ------------ -----------
Additions - 2,000 2,000
Disposals - (1,000) (1,000)
============== ============ ===========
As at 31 May 2016 2,334,455 1000 2,335,455
============== ============ ===========
Provisions
At 1 June 2013 1,867,000 - 1,867,000
Provided in the year - - -
-------------- ------------ -----------
At 31 May 2014 1,867,000 - 1,867,000
-------------- ------------ -----------
Provided in the year 467,455 - 467,455
At 31 May 2015 2,334,455 - 2,334,455
-------------- ------------ -----------
Provided in the year - - -
At 31 May 2016 2,334,455 - 2,334,455
============== ============ ===========
Net Book Value
At 31 May 2016 - 1,000 1,000
============== ============ ===========
- - -
At 31 May 2015
============== ============ ===========
At 31 May 2014 467,455 - 467,455
============== ============ ===========
All of the above investments
are unlisted.
Following the prudent write down of the intangible assets under
the requirements of IFRS in the subsidiaries, the subsidiaries'
financial statements show that they have net liabilities. The
directors have made full provision against the cost of investment
in the subsidiaries due to the net liabilities shown in the
subsidiary financial statements.
Particulars of principal subsidiary and joint venture companies
during the year, all the shares of which being beneficially held by
Feedback PLC, were as follows:
Company Activity Country Proportion
of and of Shares
incorporation held
operation
Feedback Black Non trading England 100%
Box Company Limited Ordinary
GBP1
Feedback Data GmbH Non trading Germany 100%
(liquidated Specific
October 2015) capital
Brickshield Limited Non trading England 100%
Ordinary
GBP1
Cambridge Computed Medical Imaging England 100%
Imaging Limited A Ordinary
GBP1
100% B
Ordinary
1p
TexRAD Limited Medical Imaging England 100%
Ordinary
1p
Prostate Checker Non trading England 50%
Ltd Ordinary
GBP1
TexRAD Limited is owned 100% by virtue of a
direct holding by Feedback plc of 91% and an
indirect holding via Cambridge Computed Imaging
Limited of 9%.
Feedback Data GmbH was a subsidiary of Feedback
plc following the transfer of ownership from
Feedback Data plc on 31 May 2013. The company
was liquidated in October 2015.
All the subsidiary companies have been included
in these consolidated financial statements.
During the year Feedback PLC entered into two
joint venture arrangements as follows:
Stone Checker Software Ltd
Feedback Plc invested GBP1,000 in Stone Checker
Software Ltd in July 2015 for a 50% equity interest
and subsequently licenced its TexRAD software
to it for exclusive use in relation to kidney
stone analysis. On 3 May 2016 the 50% equity
interest was sold to Free Association Books
Limited for GBP46,000 cash. This resulted in
a profit of GBP45,000.
Prostate Checker Ltd
Feedback Plc has a 50% stake in Prostate Checker
Ltd with a cost of GBP1,000, effective 26 August
2015 (date of incorporation) with QUIBIM S.L
holding the remaining 50%. This company assists
the detection and diagnosis of prostate cancer.
This company has not traded during the year.
6. PROPERTY, PLANT AND EQUIPMENT
Plant
and
Equipment Total
GROUP GBP GBP
Cost of valuation
At 31 May 2014 1,444 1,444
Additions 9,329 9,329
At 31 May 2015 10,773 10,773
Additions 104 104
---------- -------
As 31 May 2016 10,877 10,877
========== =======
Depreciation
At 31 May 2014 - -
Charge for the year 3,858 3,858
---------- -------
At 31 May 2015 3,858 3,858
Charge for the year 3,380 3,380
---------- -------
At 31 May 2016 7,238 7,238
Net Book Value
At 31 May 2016 3,639 3,639
========== =======
At 31 May 2015 6,915 6,915
========== =======
At 31 May 2014 - -
========== =======
7. INTANGIBLE ASSETS
Software Customer Patents Goodwill Total
relationships
GROUP GBP GBP GBP GBP GBP
Cost
31 May 2014 435,000 100,000 41,585 271,415 848,000
Additions 128,099 - 32,913 - 161,012
--------- --------------- -------- --------- ----------
At 31 May 2015 563,099 100,000 74,498 271,415 1,009,012
Additions - - 13,860 - 13,860
--------- --------------- -------- --------- ----------
At 31 May 2016 563,099 100,000 88,358 271,415 1,022,872
========= =============== ======== ========= ==========
Amortisation
At 31 May 2014 - - - - -
Charge for the
year 145,372 25,000 9,940 - 180,312
Impairment charge
in the year 417,727 271,415 689,142
At 31 May 2015 563,099 25,000 9,940 271,415 869,454
Charge for the
year - 25,000 17,671 - 42,671
At 31 May 2016 563,099 50,000 27,611 271,415 912,125
========= =============== ======== ========= ==========
Net Book Value
At 31 May 2016 - 50,000 60,747 - 110,747
========= =============== ======== ========= ==========
At 31 May 2015 - 75,000 64,558 - 139,558
========= =============== ======== ========= ==========
At 31 May 2014 435,000 100,000 41,585 271,415 848,000
========= =============== ======== ========= ==========
In accordance with the accounting policies and IFRS the
Directors have assessed the carrying value of the intangible
assets. In the year ended 31 May 2015, the Directors took the
prudent decision to write down the carrying value of the software
development costs in the balance sheet in order to meet the
requirements of IFRS. During the year ended 31 May 2016 all similar
development costs have been expensed as incurred. However, the
Directors believe the Group's technology has great potential and
this write down does not reflect their commercial assessment of the
value of the Group's intellectual property. Expenditure on software
development is being written off as incurred until the provisions
of IFRS are met. The customer lists and patents are deemed to have
ongoing value to the Group.
8. OTHER RECEIVABLES
Group Company
2016 2015 2016 2015
GBP GBP GBP GBP
Amounts falling due
within one year
Amounts owing by subsidiary
undertakings - - - 16,909
Other receivables 8,684 14,290 5,168 5,699
Corporation tax recoverable 37,828 32,775 - -
Prepayments 17,398 54,194 11,493 30,385
------- -------- ------- -------
63,910 101,259 16,661 52,993
======= ======== ======= =======
9. OTHER PAYABLES
Group Company
2016 2015 2016 2015
GBP GBP GBP GBP
Amounts falling due
within one year
Other payables 4,885 9,396 1,042 16
Other taxes and social
security 15,386 33,047 292 16,418
Accruals 31,750 28,701 31,750 18,024
Deferred income 103,169 193,818 - -
-------- -------- ------- -------
155,190 264,962 33,084 34,458
======== ======== ======= =======
10. SHARE CAPITAL AND RESERVES
2016 2015
GBP GBP
Authorised and issued
share capital
Ordinary shares of
0.25 pence each 509,185 476,867
============ ============
Allotted, called up
and fully paid share
capital:
Number Number
As at 1 June 2015 190,746,746 190,746,746
Issued 12,927,111 -
------------ ------------
As at 31 May 2016 203,673,857 190,746,746
------------ ------------
Share Options
Share options are granted to directors and employees. Options
are conditional on the employee completing a specific length of
service (the vesting period). The options are exercisable from the
end of the vesting period and lapse after ten years after the grant
date. The Group has no legal or constructive obligation to
repurchase or settle the options in cash.
Share options are valued using the Black-Scholes option pricing
model and no performance conditions are included in the fair value
calculations. The risk free rate was 1.64%. The expected volatility
is based on historical volatility over the last two years and is
estimated to be 25%. The average share price during the year was
1.85 pence. During the year the Company had the following share
options in issue:
Number of options
At 1 June Lapsed Exercised At 31 Exercise Exercise
2015 May 2016 price date
(pence)
21/05/14
4,800,000 800,000 1,600,000 2,400,000 1.25 to19/05/24
21/05/15
4,000,000 - - 4,000,000 3.00 to19/05/24
21/05/15
4,000,000 - - 4,000,000 5.00 to19/05/24
12,800,000 800,000 1,600,000 10,400,000
=========== ======== ========== ===========
All share options vest one year after the grant date. Each
option can only be exercised from one year after the grant date to
ten years after the date of grant.
In June 2015 1,600,000 options were exercised at a price of
1.25p.
In March 2016 800,000 options lapsed.
Warrants
Warrants were issued to the vendors of TexRAD Limited at the
time of acquisition. The warrants are exercisable from the end of
the vesting period and lapse ten years after the grant date. The
Group has no legal or constructive obligation to repurchase or
settle the warrants in cash.
Warrants are valued using the Black-Scholes pricing model and no
performance conditions are included in the fair value calculations.
The risk free rate was 1.64%. The expected volatility is based on
historical volatility over the last two years and is estimated to
be 25%. The average share price during the year was 1.85 pence.
During the year the Company had in existence the following
warrants:
Number of warrants
At 1 June Granted Cancelled At 31 Exercise Exercise
2015 May 2016 price date
(pence)
19/05/16
4,550,000 - - 4,550,000 1.25 to 19/05/24
19/05/17
18,200,000 - - 18,200,000 3.00 to 19/05/24
22,750,000 - - 22,750,000
=========== ======== ========== ===========
Reserves
The nature and purpose of each reserve within equity is as
follows:
Share premium Amount subscribed for share capital
in excess of nominal value
Capital reserve Reserve on consolidation of subsidiaries
Translation Gains and losses on the translation
reserve of overseas operations into GBP
Retained earnings All other net gains and losses
and transactions with owners
not recognised elsewhere
Convertible Amount of proceeds on issue of
debt option convertible debt relating to
reserve the equity component of the debt.
11. NOTICE OF ANNUAL GENERAL MEETING ("AGM") AND AVAILABILITY OF
REPORT AND FINANCIAL STATEMENTS
The Company hereby announces that its AGM will be held at the
offices of Allenby Capital Limited, 3 St Helen's Place, London EC3A
6AB at 10.00 a.m. on 23 November 2016.
The Company's Annual Report and Financial Statements for the
year ended 31 May 2016 are expected to be posted to shareholders,
along with the Notice of AGM, on 26 October 2016 and will be
available thereafter at the Company's registered office, Unit 5
Grange Park, Broadway, Bourn, Cambridgeshire CB23 2TA and on its
website: http://www.fbk.com/category/financial-reports/
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR BLBDGUUBBGLI
(END) Dow Jones Newswires
October 19, 2016 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2024 to May 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From May 2023 to May 2024